血液透析患者血红蛋白变异性与感染风险及全因死亡的关系
基于J-DOPPS 2012–2018年3063例血液透析患者的前瞻性队列数据,采用Cox回归分析血红蛋白变异性与全因死亡、住院及心血管、血栓或感染性不良事件的关系。中位随访2.5年,全因死亡率在第一四分位组最低,变异性更大组趋于更高(第四四分位HR 1.44,95%CI 0.99–2.08,趋势P=0.056);感染事件发生率第一四分位组低于其他四分位组(趋势P<0.01);心血管和血栓事件发生率与血红蛋白变异性无关。
要点
- 血红蛋白变异性更高与全因死亡风险趋于升高相关(第四四分位HR 1.44,95%CI 0.99–2.08)。
- 感染事件发生率在第一四分位组低于其他四分位组(趋势P<0.01)。
- 心血管和血栓事件发生率与血红蛋白变异性无关联。
核心结论
- 接受ESA治疗的维持性血液透析患者,血红蛋白变异性更高与全因死亡风险升高及尤其感染事件风险升高相关。
研究设计与样本
- 前瞻性队列研究,使用日本透析结局与实践模式研究(J-DOPPS)2012至2018年3063例血液透析患者数据,采用Cox回归模型分析。
主要发现
- 中位随访2.5年,全因死亡率在第一四分位组最低,变异性更大组趋于更高(血红蛋白变异性绝对值第四四分位HR 1.44,95%CI 0.99–2.08,趋势P=0.056)。
- 感染事件发生率第一四分位组低于其他四分位组(趋势P<0.01)。
- 该关联在血清铁蛋白较低或接受铁剂补充的患者中更为明显。
- 心血管和血栓事件发生率与血红蛋白变异性无关联。
临床怎么用
- 在管理血液透析患者贫血时,可将血红蛋白变异性作为全因死亡和感染事件的关联因素进行关注。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In the management of anemia in chronic kidney disease, hemoglobin levels often fall below or exceed target ranges. Past retrospective cohort studies of patients undergoing hemodialysis with conventional erythropoiesis stimulating agents (ESAs) found that hemoglobin level fluctuations predicted mortality and cardiovascular adverse events; long-acting agents were thereafter widely available. An updated validation by a prospective cohort study was needed. METHODS: Using Cox regression models, we evaluated associations between hemoglobin variability and all-cause death, hospitalization, and cardiovascular, thrombotic, or infectious adverse event outcomes in 3063 hemodialysis patients' data from the Japanese Dialysis Outcomes and Practice Patterns Study (J-DOPPS) from 2012 to 2018. RESULTS: During a median follow-up time of 2.5 years, all-cause mortality was lowest in the first quartile and tended to be higher in groups with greater hemoglobin variability (hazard ratio [HR]: 95% confidence interval for the fourth quartile of an absolute value of hemoglobin variability: 1.44 [0.99-2.08], P for trend = 0.056). Infectious event incidence in these patients was also lower in the first quartile than for the other quartiles (P for trend < 0.01). The association was more pronounced in patients with lower serum ferritin levels or iron supplementation. Cardiovascular and thrombotic event incidence was not associated with hemoglobin variability. CONCLUSIONS: Maintenance hemodialysis patients on ESA treatment with higher hemoglobin variability are at higher risk for all-cause mortality and particularly infectious events.
引用
- Nishi H, Wang J, Onishi Y, et al. Infectious Risk and Variability of Hemoglobin Level in Patients Undergoing Hemodialysis. Kidney Int Rep. 2023. PMID: 37705913. doi:10.1016/j.ekir.2023.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。